nanoComposix is now a Fortis Life Sciences Company. Learn more + Email Newsletter Signup

nanoComposix offers full-service lateral flow assay CDMO development services & high-capacity medical device manufacturing, making it the complete solution for start-to-finish assay production

April 20, 2021

nanoComposix is uniting its lateral flow assay development services with high-volume automated medical device manufacturing to offer fully custom start-to-finish assay production managed by industry experts. For nearly two decades, nanoComposix has been building precisely engineered and highly characterized nanomaterials for customers worldwide. As a result, the company is uniquely positioned to provide the improved particles and surface chemistry necessary to develop ultrasensitive, rapid, quantitative, point-of-care lateral flow diagnostic tests.

With the recent expansion of the nanoComposix facility to accommodate additional BioDot reel-to-reel dispensing and lamination equipment for high throughput lateral flow test manufacturing, nanoComposix is now equipped to produce up to 10 million lateral flow tests each month under its ISO 13485:2016 certified Quality Management System. Now, in addition to supplying gold reagent for high sensitivity in bulk and performing large-scale custom conjugations, nanoComposix offers a complete solution to efficiently bring reliable, reproducible, fully custom point-of-care tests to market.

“Having reel-to-reel manufacturing on-site expands the menu of options we can offer to our clients,” said Andre Alfaro, Director of Assay Development at nanoComposix. “We work incredibly hard to build strong and lasting relationships with our clients predicated on making sure all product development needs are met. If there is an unmet need, such as high volume manufacturing, nanoComposix will move mountains to make sure that client needs are met. No detail goes untouched throughout the process, starting with feasibility, and now persisting through to manufacturing.”

About nanoComposix

For nearly 20 years, nanoComposix has used its proprietary nanoscale toolkit to develop metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics. Under its ISO 13485:2016 certified Quality Management System, nanoComposix manufactures precisely engineered and highly characterized nanoparticles to facilitate the production of robust, reproducible nanoparticle conjugates at a commercial scale. Innovative solutions to the most challenging R&D questions are addressed through the establishment of open and collaborative relationships with clients. nanoComposix markets its products directly to consumers, and through distributors and licensing partners worldwide.

Visit nanoComposix online at www.nanocomposix.com.

For more information, please contact:
Dr. Elonne Petrin
Business Development
(858) 565-4227 x 161
info@nanocomposix.com